BHF PROTECT-TAVI

  • Research type

    Research Study

  • Full title

    British Heart Foundation Randomised Clinical Trial of Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (BHF PROTECT-TAVI)

  • IRAS ID

    276396

  • Contact name

    Rajesh Kharbanda

  • Contact email

    rajesh.kharbanda@ouh.nhs.uk

  • Sponsor organisation

    University of Oxford / Clinical Trials and Research Governance

  • ISRCTN Number

    ISRCTN16665769

  • Duration of Study in the UK

    5 years, 11 months, 30 days

  • Research summary

    Summary of Research

    Aortic stenosis (AS) is a common life-threatening condition, where blood flow out of the heart is restricted by narrowing of the aortic valve. There are two ways to treat AS. Transcatheter Aortic Valve Implantation (TAVI) insert a new valve inside the existing diseased valve. Surgical aortic valve replacement (AVR) involves surgery on the heart to replace the diseased valve.

    TAVI is less invasive than surgical AVR. However, there are still risks with TAVI including stroke and death. Stroke in TAVI can be caused by debris released into the bloodstream by the procedure. Devices, called cerebral embolic protection (CEP), have been developed that capture some of this debris using filters temporarily placed in the artery which provides blood to the brain. However, there is of yet no evidence that shows that CEP meaningfully reduces stroke in TAVI patients. This trial will address this evidence gap.

    In this study we will randomly assign patients receiving TAVI to receive CEP during TAVI or to the current standard of care without CEP. Potential participants will be approached prior to their TAVI procedure to discuss the trial. If they are happy to take part, full informed consent will be sought. Following the TAVI, we will assess whether participants have a stroke in the following 72 hours. We will also assess how the CEP treatment impacts on the NHS as well following-up participants for 12 months to assess their long term outcomes. We will recruit 7730 participants across the UK over 4 years.

    Summary of Results
    Why we did the study:
    Transcatheter Aortic Valve Implantation (TAVI) is a procedure used to treat aortic stenosis, a heart condition where the aortic valve becomes narrow and stiff reducing blood flow from the heart to the rest of the body. During a TAVI procedure, debris from the valve and blood vessels can be released into the bloodstream. This debris can sometimes block the arteries which supply the brain and cause a stroke. This happens in about 2 patients for every 100 that are treated with TAVI. Cerebral embolic protection (CEP) devices are filters that are placed in the arteries which supply the brain with blood. The CEP devices are designed to prevent strokes by capturing debris before it reaches the brain.
    BHF PROTECT-TAVI used the Sentinel device, which is a CEP device manufactured by Boston Scientific and is approved for use in Europe and USA.
    The BHF PROTECT-TAVI trial was run to test whether using the Sentinel CEP device during TAVI procedures can reduce the risk of stroke.

    What we did:
    The BHF PROTECT-TAVI trial recruited 7,635 people undergoing TAVI at 33 hospitals across the UK between October 2020 and October 2024.
    Approximately half the patients had their TAVI without the CEP device and the other half had their TAVI with the CEP device. The study group that patients were in was decided by chance, through a process called randomisation. This is the fairest way of comparing treatments.

    What we found:
    Within three days of the TAVI procedure, 82 patients (2.2%) in the group that did not receive the CEP device had a stroke, compared with 81 patients (2.1%) in the group that received the CEP device.
    This showed that routinely using the Sentinel CEP device during TAVI did not reduce the risk of stroke within three days of the procedure.
    The number of patients who died within three days of the procedure was similar in both groups. The number of patients who experienced a disabling stroke within eight weeks of the procedure was also similar between the groups.

    Where can I learn more about the study:
    The results were published in the New England Journal of Medicine - https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Ftrack.pstmrk.it%2F3ts%2Fwww.nejm.org%252Fdoi%252F10.1056%252FNEJMoa2415120%2FNBTI%2FLzLJAQ%2FAQ%2F02faded1-1325-4efe-8492-2e63055c38e7%2F2%2FZegY58U_o0&data=05%7C02%7Capprovals%40hra.nhs.uk%7Cecb9593afa0a419b062408df3b341e77%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C639294767184866791%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=5gRYVEePlAcY48kr4Kh64JfHnbn%2BCmRuv6xoR2O7%2BvU%3D&reserved=0
    The BHF PROTECT-TAVI Trial was funded by the British Heart Foundation and sponsored by University of Oxford

  • REC name

    Wales REC 5

  • REC reference

    20/WA/0121

  • Date of REC Opinion

    23 Apr 2020

  • REC opinion

    Favourable Opinion